Your SlideShare is downloading. ×
New Release: Endometriosis - Pipeline Review, H1 2014
New Release: Endometriosis - Pipeline Review, H1 2014
New Release: Endometriosis - Pipeline Review, H1 2014
New Release: Endometriosis - Pipeline Review, H1 2014
New Release: Endometriosis - Pipeline Review, H1 2014
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

New Release: Endometriosis - Pipeline Review, H1 2014

306

Published on

Endometriosis - Pipeline Review, H1 2014 @ http://www.researchmoz.us/endometriosis-pipeline-review-h1-2014-report.html …

Endometriosis - Pipeline Review, H1 2014 @ http://www.researchmoz.us/endometriosis-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
306
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Endometriosis - Pipeline Review, H1 2014 Endometriosis - Pipeline Review, H1 2014 Summary Global Markets Directs, Endometriosis - Pipeline Review, H1 2014, provides an overview of the Endometriosiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Endometriosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 8 list Of Figures 9 introduction 10 global Markets Direct Report Coverage 10 endometriosis Overview 11 therapeutics Development 12 pipeline Products For Endometriosis - Overview 12 pipeline Products For Endometriosis - Comparative Analysis 13 endometriosis - Therapeutics Under Development By Companies 14 endometriosis - Therapeutics Under Investigation By Universities/institutes 17 endometriosis - Pipeline Products Glance 19 late Stage Products 19 clinical Stage Products 20 Endometriosis - Pipeline Review, H1 2014
  • 2. early Stage Products 21 unknown Stage Products 22 endometriosis - Products Under Development By Companies 23 endometriosis - Products Under Investigation By Universities/institutes 25 endometriosis - Companies Involved In Therapeutics Development 26 euroscreen S.a. 26 takeda Pharmaceutical Company Limited 27 neurocrine Biosciences, Inc. 28 astellas Pharma Inc. 29 kissei Pharmaceutical Co., Ltd. 30 sk Chemicals Co., Ltd. 31 bayer Ag 32 addex Therapeutics 33 evotec Ag 34 valirx Plc 35 repros Therapeutics Inc. 36 dongkook Pharmaceutical Co., Ltd. 37 camurus Ab 38 lipicard Technologies Limited 39 orphagen Pharmaceuticals, Inc. 40 peptron, Inc. 41 preglem Sa 42 endoceutics, Inc. 43 isifer Ab 44 elexopharm Gmbh 45 apavadis Biotechnologies Srl 46 abbvie Inc. 47 balonco Gmbh 48 forendo Pharma Oy 49 endometriosis - Therapeutics Assessment 50 assessment By Monotherapy Products 50 assessment By Combination Products 51 assessment By Target 52 assessment By Mechanism Of Action 55 assessment By Route Of Administration 58 assessment By Molecule Type 60 drug Profiles 62 elagolix Sodium - Drug Profile 62 product Description 62 mechanism Of Action 62 r&d Progress 62 leuprolide Acetate Sr - Drug Profile 64 product Description 64 mechanism Of Action 64 r&d Progress 64 degarelix - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 (acolbifene + Dhea + Gnrh Agonist) - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 relugolix - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 telapristone Acetate - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 pgl-2001 - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 klh-2109 - Drug Profile 72 product Description 72 mechanism Of Action 72 Endometriosis - Pipeline Review, H1 2014
  • 3. r&d Progress 72 asp-1707 - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 endole - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 bentamapimod - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 teverelix - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 bay-1026153 - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 adx-68692 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 esn-364 - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 val-201 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 leuprolide Acetate - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 gnrh Antagonists - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 small Molecule To Inhibit 17 Beta-hsd1 For Endometriosis And Breast Cancer - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 hsd Research Program - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 small Molecules For Endometriosis - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 nce-403 - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 aminopeptidase A Program - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 meta Program - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 drugs To Inhibit Gnrh Receptor For Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology And Women Health - Drug Profile 90 product Description 90 mechanism Of Action 90 Endometriosis - Pipeline Review, H1 2014
  • 4. r&d Progress 90 eve-104 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 ec-304 - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 triptorelin Pamoate Biosimilar - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 goserelin Biosimilar - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 lt-6121 - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 kisspeptin Peptide Antagonists - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 small Molecule To Inhibit 17hsd1 For Endometriosis - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 recombinant Pigment Epithelium Derived Factor - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 vpe-001 - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 small Molecule To Inhibit 17beta-hydroxysteroid Dehydrogenase Type1 For Endometriosis And Estrogen Dependent Cancers - Drug Profile 100 product Description 100 mechanism Of Action 100 r&d Progress 100 drug Targeting Rerg For Endometriosis - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 small Molecules To Inhibit Prostanoid Ep2 And Ep4 Receptors For Endometriosis - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 steroidogenic Factor-1 Antagonists - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 program For Women Health - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 emmprin-conjugates - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 drugs Inhibiting Axl/gas6 Signaling - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 drug To Inhibit C-jun For Endometriosis - Drug Profile 108 product Description 108 mechanism Of Action 108 Endometriosis - Pipeline Review, H1 2014
  • 5. r&d Progress 108 endometriosis - Recent Pipeline Updates 109 endometriosis - Dormant Projects 122 endometriosis - Discontinued Products 123 endometriosis - Product Development Milestones 124 featured News & Press Releases 124 oct 03, 2013: Valirx Files Phase Ib/dose Escalation Study For Val201 124 aug 29, 2013: Neurocrine Biosciences Announces The Start Of Second Phase Iii Study Of Elagolix In Endometriosis 124 apr 25, 2013: Valirx Receives Australian Patent For Val201 125 nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 125 oct 08, 2012: Repros Therapeutics's Proellex Receives Fda Acceptance For Reclassification Of Clinical Hold Status 126 aug 27, 2012: Fda Provides Recommendations For Phase Ii Protocol For Repros' Proellex In Treatment Of Endometriosis 127 jul 30, 2012: Fda Schedules Meeting With Repros To Discuss Phase Ii Protocol For Proellex For Treatment Of Endometriosis 127 jul 16, 2012: Fda Provides Guidance To Repros For Conducting Phase Ii Study Of Proellex In Treatment Of Endometriosis 128 jun 05, 2012: Abbott Initiates Phase Iii Study Of Elagolix In Patients With Endometriosis 128 may 29, 2012: Repros Provides Updates On Proellex Clinical Programs Status 128 appendix 130 methodology 130 coverage 130 secondary Research 130 primary Research 130 expert Panel Validation 130 contact Us 131 disclaimer 131 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Endometriosis - Pipeline Review, H1 2014

×